Sapitinib

Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist with a rapid onset of action designed for intranasal administration, used to treat Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells.


Cat. No.: EX-A5306	Purity: >98%

	Chemical structure of Sapitinib

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	750	In-stock
250mg	1150	In-stock
500mg	1850	In-stock
1g	2850	In-stock
5g	get quote	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	MSP-2017
CAS No.	1593673-23-4
Purity	>98%
Formula	C27H36N2O4
Mol Weight	452.5857
Color	Brown to wine red
State	Oil
Solubility	Soluble in Ethanol 120 mg/mL
Shelf Life	>3 years if stored properly
Storage	Pure form -20℃ 3 years, 4°C 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Stambler BS, et al. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497. [2]. Milestone Pharmaceuticals Announces USAN Approval of Generic Name “Etripamil” for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia.
CoA	CoA of Sapitinib

Smiles:	O=C(OC)C1=CC=CC(CCN(CCC[C@](C2=CC=C(OC)C(OC)=C2)(C#N)C(C)C)C)=C1


		Search